文献速递肾癌与肾肿瘤

小肾癌主动监测中局部治疗与转移发生率:加拿大全国多中心前瞻队列

Incidence of Local Treatment and Metastasis During Active Surveillance for Patients With a Small Renal Mass in a National Multicenter Prospective Cohort.
PubMed 文献 · J Urol · 2025-08-22

研究纳入加拿大肾脏癌症信息系统2011至2023年1393例≤4cm单发小肾癌起始主动监测(AS)患者,中位随访4.0年,238例接受局部治疗,29例发生转移。5年局部治疗累积发生率21%,转移累积发生率2.3%,支持AS作为安全的初始管理策略。

要点

  • ≤4cm小肾癌起始AS,5年局部治疗累积发生率21%、转移2.3%。
  • 2年局部治疗和转移累积发生率分别为8.4%和0.67%。
  • 29例转移者中23例此前已出现大小或生长速率进展。

核心结论

  • 选择主动监测的小肾癌患者5年局部治疗与转移累积发生率低,支持AS作为安全的初始管理方式。

研究设计与样本

  • 基于加拿大肾脏癌症信息系统的全国多中心前瞻性队列,纳入2011年1月至2023年1月≤4cm单发肾肿块并选择AS的患者1393例。

主要发现

  • 中位随访4.0年(95%CI 2.1-6.4)期间238例接受局部治疗,其中195例为保留肾单位手术。
  • 2年和5年局部治疗累积发生率分别为8.4%(95%CI 6.9-10)和21%(95%CI 19-24)。
  • 29例发生转移,2年和5年转移累积发生率分别为0.67%(95%CI 0.32-1.3)和2.3%(95%CI 1.5-3.5)。
  • 29例转移患者中23例按大小或生长速率界值判定为进展,7例在发现转移前已接受根治性局部治疗。

关键数值与推荐

  • 局部治疗进展定义为起始AS后接受确定性局部治疗。
  • 生长速率进展定义为>0.5cm/y,大小进展定义为>4cm,复合进展为二者任一。

临床怎么用

  • 对≤4cm单发小肾癌可告知患者AS的5年局部治疗风险约21%、转移风险约2.3%,作为初始管理选择之一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The objective of this study was to determine the incidence of local treatment and incidence of metastasis for patients with a solitary small renal mass (SRM; ≤4 cm) initiating active surveillance (AS). MATERIALS AND METHODS: Patients enrolled in the Canadian Kidney Cancer information system between January 2011 and January 2023 with a solitary renal mass ≤ 4 cm opting for AS were included. The primary outcome was local treatment progression, achieved if the patient received definitive local treatment after initiating AS. The secondary outcomes were growth rate progression (>0.5 cm/y), size progression (>4 cm), composite progression (either size or growth rate progression), and development of metastases. RESULTS: The Canadian Kidney Cancer information system included 1393 patients who initiated AS for an SRM ≤ 4 cm during the study period. At a median follow-up of 4.0 years (95% CI 2.1-6.4), 238 patients received local treatment, and of these, 195 were nephron sparing. Two- and 5-year cumulative incidence of treatment was 8.4% (95% CI 6.9-10) and 21% (95% CI 19-24), respectively. Twenty-nine patients developed metastasis. Two- and 5-year cumulative incidence of metastasis was 0.67% (95% CI 0.32-1.3) and 2.3% (95% CI 1.5-3.5), respectively. Of the 29 patients who developed metastases, 23 had progressed using size or growth rate cutoffs, and 7 had received local treatment with curative intent before the identification of metastases. CONCLUSIONS: Patients choosing surveillance for an SRM have low cumulative incidence of local treatment and metastasis at 5 years, demonstrating AS is a safe initial management approach.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Lavallée LT, Finelli A, Tanguay S, et al. Incidence of Local Treatment and Metastasis During Active Surveillance for Patients With a Small Renal Mass in a National Multicenter Prospective Cohort. J Urol. 2025. PMID: 40845132. doi:10.1097/JU.0000000000004746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。